Chongqing Peg-Bio Biopharm Co., Ltd.: Phase 2 study completed, 54 enrolled (Thrombocytopenia Associated With Chronic Liver Disease)
Chongqing Peg-Bio Biopharm Co., Ltd.: Phase 2 study completed, 54 enrolled (Thrombocytopenia Associated With Chronic Liver Disease). Its enrollment of 54 is below the median of 80 (36th percentile). Dated 14 days ago, it is in the active follow-up window. Score 90/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 54 · 36th percentile of 8,879 ClinicalTrialStartPulse records · 0.7x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Chongqing Peg-Bio Biopharm Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure |
| NCT ID | NCT07446491 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Thrombocytopenia Associated With Chronic Liver Disease |
| Intervention types | drug |
| Target enrollment | 54 |
| Site countries | China |
| Posted | 2026-03-03 |
| Planned start | 2025-06-06 |
| Event | Completed |
| Event date | 2026-10-15 |
| Last update posted | 2026-10-22 |
| enrollment percentile | 36th of 8,879 (median 80, 0.7x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Chongqing Peg-Bio Biopharm Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Chongqing Peg-Bio Biopharm Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-22
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Chongqing Peg-Bio Biopharm Co., Ltd. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Chongqing Peg-Bio Biopharm Co., Ltd.'s enrollment: 36th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
90 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
What is the ClinicalTrialStartPulse record for Chongqing Peg-Bio Biopharm Co., Ltd.?
Chongqing Peg-Bio Biopharm Co., Ltd.'s Phase 2 study (NCT07446491) in Thrombocytopenia Associated With Chronic Liver Disease, first posted 2026-03-03: completed (2026-10-15), in an update posted 2026-10-22.
How does Chongqing Peg-Bio Biopharm Co., Ltd. compare to other ClinicalTrialStartPulse records?
Its enrollment of 54 is below the median (36th percentile); smaller records often move faster and face less competition. It is fresh: dated 14 days ago, inside the window where early outreach matters most. Its Score of 90/100 puts it among the stronger signals in this feed.
Chongqing Peg-Bio Biopharm Co., Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Chongqing Peg-Bio Biopharm Co., Ltd. | NONUS | 54 | 36th | 2026-10-22 |
| BeOne Medicines | NONUS | 100 | 60th | 2026-11-03 |
| Nurix Therapeutics, Inc. | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 166 | 73rd | 2026-11-03 |
Related records
- Nurix Therapeutics, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Teva Branded Pharmaceutical Products R&D LLC
- Genmab
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Apogee Therapeutics, Inc.
- Janssen Research & Development, LLC
- BeOne Medicines
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: Outside the US only
How to monitor Chongqing Peg-Bio Biopharm Co., Ltd. and peer phase 2 records
Get new ClinicalTrialStartPulse records like Chongqing Peg-Bio Biopharm Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.